Biovista announces positive efficacy results in a pre-clinical trial of BVA-201 for Multiple Sclerosis

September 9, 2009Press Releases

CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ — Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both … Read More

Biovista Inc. to present at upcoming CHI drug repositioning summit

September 9, 2009Events

Charlottesville, VA (9 September 2009): Biovista Inc. announced today that it will present at the CHI  Drug Repositioning Summit in Boston, MA, Oct. 13-14, 2009. The presentation will highlight the efficiencies of repositioning as a development strategy, and introduce Biovista’s proprietary platform for repositioning and adverse event profiling. BVA-101, 201 and 601 will be presented as … Read More

Biovista Inc. to present at upcoming Marcus Evans repositioning con

September 8, 2009Events

 Charlottesville, VA (8 September 2009) : Biovista announced today that it will present at the Marcus Evans 2nd Annual Drug Repositioning and Pipeline Enhancement conference in Philadelphia, PA, Sept. 17-18, 2009. The presentation will cover the advantages of repositioning as a component of portfolio development and lifecycle management, with specific Biovista drug case studies in … Read More

Biovista sponsors the 2009 Notch Meeting

September 2, 2009Events

Athens, GR, September 2nd, 2009 — Biovista Inc. is pleased to announce its sponsoring of the international 2009 Notch Meeting to be held in Athens, Greece, from September 27th to October 1st, 2009. The Notch Meeting is a biennial event on general Notch research that aims to reflect the diversity of Notch research and bring together researchers … Read More

Biovista Inc. announces positive efficacy results in a pre-clinical trial of its BVA-601 drug for Epilepsy

June 23, 2009Press Releases

 CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ — Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant … Read More